Search Within

Genitourinary Oncology Service

  1. "Sujata Patil"
Formats
  1. Meeting Abstract (60)
  2. Journal Article (52)
Groups
  1. Biostatistics Service (112)
  2. Department of Medicine (112)
  3. Epidemiology and Biostatistics (112)
  4. Solid Tumor Oncology Division (112)
  5. Survivorship Research (58)
  6. Surgery (48)

More Groups

People
  1. Sujata Patil (112)
  2. Robert Motzer (93)
  3. Darren Feldman (81)
  4. Martin Voss (42)
  5. George Bosl (35)
  6. Chung-Han Lee (27)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (12)
  4. 2020 (9)
  5. 2019 (9)
  6. 2018 (9)

More Years

Publications
  1. Journal of Clinical Oncology (63)
  2. Clinical Genitourinary Cancer (8)
  3. Cancer (6)
  4. Clinical Cancer Research (6)
  5. Investigational New Drugs (3)
  6. Annals of Oncology (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (64)
  2. Elsevier Inc. (11)
  3. American Association for Cancer Research (9)
  4. Wiley Blackwell (6)
  5. Biomed Central Ltd (4)
  6. Oxford University Press (4)

More Publishers

Results (112)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of margin width on local recurrence (LR) in triple-negative (TN) breast cancer treated with breast-conserving therapy (BCT)
    Meeting Abstract

    Pilewskie, M. L.; Ho, A. Y.; Orell, E.; Stempel, M.; Chen, Y.; Eaton, A.; Patil, S.; Morrow, M.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase I/II study of paclitaxel plus ifosfamide (TI) followed by high-dose paclitaxel, ifosfamide, and carboplatin (TIC) with autologous stem cell transplant (ASCT) for salvage treatment of germ cell tumors (GCT)
    Meeting Abstract

    Jia, X.; Feldman, D. R.; Glezerman, I.; Van Alstine, L. J.; Bajorin, D. F.; Fischer, P.; Hughes, A.; Sheinfeld, J.; Bains, M. S.; Reich, L.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Paclitaxel, ifosfamide, and cisplatin (TIP) efficacy for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT)
    Meeting Abstract

    Feldman, D. R.; Hu, J.; Dorff, T. B.; Patil, S.; Van Alstine, L. J.; Momen, L.; Carousso, M.; Hughes, A.; Snively-Solomon, J.; Ketchens, C.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Targeted therapy for renal cell carcinoma (RCC) with brain metastasis: Overall survival (OS) and safety
    Meeting Abstract

    Bastos, D. A.; Molina, A. M.; Jia, X.; Velasco, S.; Patil, S.; Voss, M. H.; Feldman, D. R.; Motzer, R. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Long-term response to sunitinib therapy for metastatic renal cell carcinoma
    Journal Article

    Molina, A. M.; Jia, X.; Feldman, D. R.; Hsieh, J. J.; Ginsberg, M. S.; Velasco, S.; Patil, S.; Motzer, R. J.
    Clinical Genitourinary Cancer (2013)

    Fulltext@MSK | Save
  • Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and older
    Journal Article

    Feldman, D. R.; Voss, M. H.; Jacobsen, E. P.; Jia, X.; Suarez, J. A.; Turkula, S.; Sheinfeld, J.; Bosl, G. J.; Motzer, R. J.; Patil, S.
    Cancer (2013)

    Fulltext@MSK | Save
  • Serum tumor marker (STM) decline rates during high-dose chemotherapy (HDCT) to predict outcome for germ cell tumor (GCT) patients (pts)
    Meeting Abstract

    Feldman, D. R.; Voss, M. H.; Jia, X.; Van Alstine, L. J.; Patil, S.; Fischer, P.; Sheinfeld, J.; Bosl, G. J.; Motzer, R. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Improvement in overall survival of patients with advanced renal cell carcinoma: Prognostic factor trend analysis from an international data set of clinical trials
    Journal Article

    Patil, S.; Manola, J.; Elson, P.; Negrier, S.; Escudier, B.; Eisen, T.; Atkins, M.; Bukowski, R.; Motzer, R. J.
    Journal of Urology (2012)

    Fulltext@MSK | Save
  • Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
    Journal Article

    Patil, S.; Figlin, R. A.; Hutson, T. E.; Michaelson, M. D.; Negrier, S.; Kim, S. T.; Huang, X.; Motzer, R. J.
    British Journal of Cancer (2012)

    Fulltext@MSK | Save
  • Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
    Journal Article

    Molina, A. M.; Feldman, D. R.; Voss, M. H.; Ginsberg, M. S.; Baum, M. S.; Brocks, D. R.; Fischer, P. M.; Trinos, M. J.; Patil, S.; Motzer, R. J.
    Cancer (2012)

    Fulltext@MSK | Save